Fusion oncogenes, such as RET- and NTRK-gene fusions, are associated with more invasive pediatric thyroid cancers, correlating with the highest risk of metastases and a lower likelihood of achieving remission one year after initial therapy, according to a new study by researchers at Children’s Hospital of Philadelphia (CHOP). The findings, which were published in the